Table 4.
Baseline characteristics in patients with and without myocardial injury
| Characteristics | Myocardial injury | Without myocardial injury | P-value |
|---|---|---|---|
| (n = 106) | (n = 565) | ||
| Age (years), median (IQR) | 73 (66–80) | 57 (43–70) | <0.001 |
| Gender (male), n (%) | 58 (54.7) | 264 (46.7) | 0.139 |
| Comorbidities, n (%) | |||
| Hypertension | 63 (59.4) | 136 (24.1) | <0.001 |
| Diabetes | 25 (23.6) | 72 (12.7) | 0.006 |
| Coronary heart disease | 29 (27.4) | 31 (5.5) | <0.001 |
| Chronic renal disease | 17 (16.0) | 11 (1.9) | <0.001 |
| Chronic obstructive pulmonary disease | 10 (9.4) | 13 (2.3) | 0.001 |
| Cancer | 8 (7.5) | 15 (2.7) | 0.019 |
| Chronic heart failure | 13 (12.3) | 9 (1.6) | <0.001 |
| Cerebrovascular disease | 11 (10.4) | 11 (1.9) | <0.001 |
| Atrial fibrillation | 1 (0.9) | 6 (1.1) | 1.000 |
| Laboratory findings, median (IQR) | |||
| Leucocyte count, ×109/L | 9.0 (6.2–13.3) | 5.3 (4.0–7.3) | <0.001 |
| Neutrophil rate, % | 88 (82–92) | 68 (59–79) | <0.001 |
| Lymphocyte rate, % | 8 (4–12) | 21 (14–28) | <0.001 |
| Alanine aminotransferase, U/L | 29 (18–43) | 23 (16–36) | 0.527 |
| Aspartic transaminase, U/L | 36 (27–52) | 26 (20–34) | <0.001 |
| Creatinine, μmol/L | 67 (57–117) | 55 (48–65) | <0.001 |
| C-reactive protein, mg/L | 88 (60–147) | 29 (8–64) | <0.001 |
| Procalcitonin, ng/mL | 0.23 (0.09–0.69) | 0.05 (0.03–0.09) | <0.001 |
| CK-MB, ng/mL | 2.81 (1.45–5.72) | 0.85 (0.58–1.21) | <0.001 |
| MYO, μg/L | 125 (66–343) | 34 (24–62) | <0.001 |
| cTnI, ng/mL | 0.159 (0.075–0.695) | 0.006 (0.006–0.007) | <0.001 |
| NT-proBNP, pg/mL | 1346 (474–3018) | 133 (50–265) | <0.001 |
IQR, interquartile range; CK-MB, creatinine kinase-myocardial band; MYO, myoglobin; cTnI, cardiac troponin I; NT-proBNP, N-terminal pro-B-type natriuretic peptide.